GENOMIC MEDICINE AND PERSONALIZED MANAGEMENT OF SEPSIS
https://doi.org/10.21292/2078-5658-2017-14-3-35-43
Abstract
The review is devoted to one of the most critical issues of modern intensive care – personalized management of sepsis. The current definition of genomics has been given, and data available on the above issue have been analyzed, advantages and limitations of this approach in the intensive care have been discussed. The special emphasis is put on the prospect of using genetic biomarkers for sepsis severity score and prediction of sepsis outcome.
About the Authors
P. I. Mironov
Bashkirsky State Medical University, Ufa
Russian Federation
Professor of Pediatric Surgery Department with IDPO Training Course
Russian Federation
Professor of Pediatric Surgery Department with IDPO Training Course
A. U. Lekmanov
Research Institute of Children's Surgery by N. I. Pirogov Russian Research Institute Medical University, Moscow
Russian Federation
Doctor of Medical Sciences, Professor, Chief Researcher
Russian Federation
Doctor of Medical Sciences, Professor, Chief Researcher
References
1. Abraham E. New definitions for sepsis and septic shock: continuing evolution but with much still to be done. JAMA, 2016, vol. 315, pp. 757-759.
2. Almansa R., Heredia-Rodríguez M., Gomez-Sanchez E. et al. Transcriptomic correlates of organ failure extent in sepsis. J. Infect., 2015, vol. 70, no. 4, pp. 445-456.
3. Bagshaw S.M., McDermid R.C. The role of frailty in outcomes from critical illness. Curr. Opin. Crit. Care, 2013, vol. 19, no. 5, pp. 496-503.
4. Bermejo-Martin J.F., Tamayo E., Andaluz-Ojeda D. et al. Characterising Systemic Immune Dysfunction Syndrome (SIDS) to fill in the gaps of SEPSIS-2 and SEPSIS-3 definitions. Chest, 2017(Accepted).
5. Buchman T.G., Billiar T.R., Elster E. et al. Precision medicine for critical illness and injury. Crit. Care Med., 2016, vol. 44, pp. 1635-1638.
6. Chan I. S., Ginsburg G.S. Personalized medicine: progress and promise. Ann. Rev. Genomics Hum. Genet., 2011, vol. 12, pp. 217-244.
7. Cohen J., Vincent J.L., Adhikari N.K. et al. Sepsis: A roadmap for future research. Lancet Infect. Dis., 2015, vol. 15, pp. 581-614.
8. Collins F.S., Varmus H. A new initiative on precision medicine. New Engl. J. Med., 2015, vol. 372, pp. 793-795.
9. Cong L., Ran F.A., Cox D. et al. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, vol. 339, pp. 819-823.
10. Cuenca A.G., Gentile L.F., Lopez M.C. et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit. Care Med., 2013, vol. 41, no. 5, pp. 1175-1185.
11. Davenport E.E., Burnham K.L., Radhakrishnan J. et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med., 2016, vol. 4, no. 4, pp. 259-271.
12. Delano M.J., Ward P.A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Invest., 2016, vol. 126, no. 1, pp. 23-31.
13. Ferrer R., Martin-Loeches I., Phillips G. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Crit. Care Med., 2014, vol. 42, pp. 1749-1755.
14. Gaj T., Gersbach Ch.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, 2013, vol. 31, no. 7, pp. 397-404.
15. Gattinoi L., Tonetti T., Quintel M. Improved survival in critically ill patients: are large RCTs more useful then personalized medicine? We are not shure. Intens. Care Med., 2016, vol. 42, no. 11, pp. 1781-1783.
16. Goodman D.M., Livingston E.H. Genomic Medicine. JAMA, 2013, vol. 309, no. 14, pp. 1544.
17. Knaus W.A., Zimmerman J.E., Wagner D.P. et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit. Care Med., 1981, vol. 9, no. 8, pp. 591-597.
18. Knox D.B., Lanspa M.J., Kuttler K.G. et al. Phenotypic clusters within sepsisassociated multiple organ dysfunction syndrome. Intens. Care Med., 2015, vol. 41, pp. 814-822
19. Lander E.S., Linton L.M., Birren B. et al. Initial sequencing and analysis of the human genome. Nature, 2001, vol. 409, pp. 860-921.
20. Laxminarayan R., Duse A., Wattal C. et al: Antibiotic resistance-the need for global solutions. Lancet Infect. Dis., 2013, vol. 13, pp. 1057-1058.
21. Leentjens J., Kox M., van der Hoeven J.G. et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am. J. Respir. Crit. Care Med., 2013, vol. 187, no. 12, pp. 1287-1293.
22. Li R., Fang L., Tan Sh. Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity. Cell. Research, 2016, vol. 26, pp. 1273-1287.
23. Liang P., Xu Y., Zhang X. et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell., 2015, vol. 6, no. 5, pp. 363-372.
24. Maslove D.M., Wong H.R. Gene expression profiling in sepsis: timing, tissue, and translational considerations. Trends Mol. Med., 2014, vol. 20, pp. 204-213.
25. Maslove D.M., Lamontagne F., Marshall J.C. et al. A path to precision in the ICU. Crit. Care, 2017, vol. 21:79. DOI 10.1186/s13054–017–1653–x.
26. Mathias B., Lipori G., Lyle L. et al. Integrating «big data» into surgical practice. Surgery, 2016, vol. 159, pp. 371-374.
27. Opal S.M., Dellinger R.P., Vincent J.L. et al. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit. Care Med., 2014, vol. 42, pp. 1714-1721.
28. Parnell G., McLean A., Booth D. et al. Aberrant cell cycle and apoptotic changes characterise severe influenza A infection – a meta-analysis of genomic signatures in circulating leukocytes. PLoS One, 2011, vol. 6, pp. e17186.
29. Parnell G.P.,Tang B.M., Nalos M. et al. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions. Shock, 2013, vol. 40, no. 3, pp. 166-174.
30. Peltonen L., McKusick V.A. Dissecting human disease in the postgenomic era. Science, 2001, vol. 291, pp. 1224-1229.
31. Prescott H.C., Calfee C.S., Thompson B.T. et al. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am. J. Respir. Crit. Care Med., 2016, vol. 194, pp. 147-155.
32. Puthucheary Z.A., Wischmeyer P. Predicting critical illness mortality and personalizing therapy: moving to multidimensional data. Crit. Care, 2017, vol. 21, 20 DOI 10.1186/s13054–016–1597–6
33. Rello J., Valenzuela-Sánchez F. Septic shock in the era of precision medicine. J. Thorac. Dis., 2016, vol. 8, pp. 1022-1023.
34. Russell J.A. Genomics and pharmacogenomics of sepsis: so close and yet so far. Crit. Care, 2016, vol. 42, pp. 1-4.
35. Shankar-Hari M. et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA, 2016, vol. 315, pp. 775-787.
36. Simpson S.O. New sepsis criteria: a change we should not make. Chest, 2016, vol. 149, no. 5, pp. 1117-1118.
37. Sims C.R., Nguyen T.C., Mayeux P.R. Could biomarker direct therapy for the septic patients? J. Pharmacol. Exp. Ther., 2016, vol. 357, no. 2, pp. 228-239.
38. Singer M., Deutschman C.S., Seymour C.W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA, 2016, vol. 315, pp. 801-810.
39. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med., 2017, vol. 45, no. 3, pp. 486-552.
40. Sweeney T.E., Wong H.R. Risk stratification and prognosis in sepsis: what have we learned from microarrays? Clin. Chest Med., 2016, vol. 37, pp. 209-218.
41. Sweeney T.E., Khatri P. Benchmarking sepsis gene expression diagnostics using public data. Crit. Care Med., 2017, vol. 45, pp. 1-10.
42. Sweeney T.E., Perumal T.M., Henao R. et al. Mortality prediction in sepsis via gene expression analysis: a community approach. bioRxiv. preprint first posted online Dec. 19, 2016; doi: http://dx.doi.org/10.1101/095489
43. Tang В.М.Р., McLean A.S., Dawes I.W. et al. Gene-expression profiling in sepsis diagnosis. Am. J. Respir. Crit. Care Med., 2007, vol. 176, pp. 676-684.
44. Tsalik E.L., Langley R.J., Dinwiddie D.L. et al. An integrated transcriptome and expressed variant analysis of sepsis survival and death. Genome Med., 2014, vol. 6, no. 11, pp. 111.
45. Wong H.R., Shanley T.P., Sakthivel B. et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol. Genomics., 2007, vol. 30, no. 2, pp. 146-155.
46. Wong H.R., Cvijanovich N.Z., Anas N. et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am. J. Respir. Crit. Care Med., 2015, vol. 191, no. 3, pp. 309-315.
47. Wong H.R., Weiss S.L., Giuliano Jr.J.S. et al. Testing the Prognostic Accuracy of the Updated Pediatric Sepsis Biomarker Risk Model. PLoS ONE, 2016, vol. 9, no. 1, pp. e86242.
48. Wong H.R., Cvijanovich N.Z., Anas N. et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers: PERSEVERE–XP. Am. J. Resp. Crit. Care Med., 2017, Accepted: March 20, 2017 DOI: http://dx.doi.org/10.1164/rccm.201701–0066OC
49. Vogel and Motulski’s Human Genetics: Problems and Approaches. Springer, 2009.
Review
For citations:
Mironov P.I., Lekmanov A.U. GENOMIC MEDICINE AND PERSONALIZED MANAGEMENT OF SEPSIS. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2017;14(3):35-43. (In Russ.) https://doi.org/10.21292/2078-5658-2017-14-3-35-43
Email this article 